Exome sequence analysis of Kaposiform hemangioendothelioma: identification of putative driver mutations



Título del documento: Exome sequence analysis of Kaposiform hemangioendothelioma: identification of putative driver mutations
Revista: Anais brasileiros de dermatologia
Base de datos: PERIÓDICA
Número de sistema: 000404087
ISSN: 0365-0596
Autores: 1
1
1
1
1
1
Instituciones: 1Kumamoto University, Faculty of Life Sciences, Kumamoto, Kyusyu. Japón
Año:
Periodo: Nov-Dic
Volumen: 91
Número: 6
Paginación: 748-753
País: Brasil
Idioma: Inglés
Tipo de documento: Artículo
Enfoque: Analítico, descriptivo
Resumen en inglés Kaposiform hemangioendothelioma is a rare, intermediate, malignant tumor. The tumor's etiology remains unknown and there are no specific treatments. OBJECTIVE: In this study, we performed exome sequencing using DNA from a Kaposiform hemangioendothelioma patient, and found putative candidates for the responsible mutations. METHOD: The genomic DNA for exome sequencing was obtained from the tumor tissue and matched normal tissue from the same individual. Exome sequencing was performed on HiSeq2000 sequencer platform. RESULTS: Among oncogenes, germline missense single nucleotide variants were observed in the TP53 and APC genes in both the tumor and normal tissue. As tumor-specific somatic mutations, we identified 81 candidate genes, including 4 nonsense changes, 68 missense changes and 9 insertions/deletions. The mutations in ITGB2, IL-32 and DIDO1 were included in them. CONCLUSION: This is a pilot study, and future analysis with more patients is needed to clarify: the detailed pathogenesis of this tumor, the novel diagnostic methods by detecting specific mutations, and the new therapeutic strategies targeting the mutation
Disciplinas: Medicina
Palabras clave: Dermatología,
Oncología,
Genética,
Mutaciones génicas,
Exoma,
Secuencia génica,
Hemangioendotelioma
Keyword: Medicine,
Dermatology,
Oncology,
Genetics,
Gene mutations,
Exome,
Gene sequence,
Hemangioendothelioma
Texto completo: Texto completo (Ver HTML)